“I think the prostate cancer community has benefited a lot in the past several years with the advent of enhanced imaging tools to help us better stage patients with prostate cancer both at their initial diagnosis and if, unfortunately, they have a recurrence,” says Edward M. Schaeffer, MD, PhD.
"I would say that the take-home message of the study is that these immunosuppressive medications have alterations in the microbiology in a lot of these organs and a lot of these tumors," says Conor Driscoll, MD.
"Northwestern Madison's urology program has a very robust clinical research enterprise," says Edward M. Schaeffer, MD, PhD.
"The NCCN guidelines are unique in that they're almost constantly updated in real time," says Edward M. Schaeffer, MD, PhD.
"Prostate cancer showed a decreased risk, which we thought was very interesting, because it was the only cancer for which that signal existed, that there is possibly a protective effect of these medications," says Conor Driscoll, MD.
“Looking at the impressive results for cohort K, with enfortumab, it's amazing what that is going to provide our patients,” says Joshua J. Meeks, MD, PhD.
“We're still very interested in early-stage bladder cancer, those at high risk do not respond to BCG,” says Joshua J. Meeks, MD, PhD.
"It pretty much has been adopted around the world so that about 80% of men who are diagnosed with low-risk prostate cancer go on active surveillance. In Sweden, it's about 80%. That's considered the goal. But the United States has been slow in adopting this," says William J. Catalona, MD.
"About 80% of the patients who underwent treatment showed a very strong reduction in tryptase levels," says Praveen Thumbikat, DVM, PhD.
Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery.
"Because we don't have calibration data on Black, or Hispanic, or Asian men in many of these risk tools, we don't know the impact of these tools as screening tests," says Adam Murphy, MD, MBA, MSCI.
“I think, overall, nomograms are a really powerful tools just because there are so many different clinical variables that we consider when we talk to patients about whether to proceed with prostate biopsy,” says Eric Li, MD.
The update was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.
"Patients with a prior BPH procedure were on average older than our HoLEP controls; however, there were no other differences in preoperative patient characteristics or postoperative functional outcomes," said Nicholas S. Dean, MD.
"Overall, we found that Prostate Health Index above 55 preoperatively was associated with any incidental prostate cancer as well as clinically significant prostate cancer," says Eric Li, MD.
“In terms of next steps, we are collaborating with other institutions…to see how our model performs in their patient populations,” says Eric Li, MD.
“He’s had just such a huge impact for me as a role model, a teacher, a wonderful support system, just such a kind-hearted person,” says Stacy Loeb, MD, MSc, PhD (hon).
“We were actually quite pleased with how well our model performed, particularly in the independent cohort that was separate from our training cohort,” says Eric Li, MD.
“We want to minimize our negative biopsies and diagnosis of grade group 1 cancers,” says Rashid Siddiqui, MD.
"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
“You can really see the difference with the patients who go for physical therapy and the ones who don't,” says Ricardo M. de Oliveira Soares, MD.
"We wanted to make sure that it was highlighted that men really need to be screened, and it should be covered by insurance," says Adam Murphy, MD, MBA, MSCI.
"There's a potential for a more nuanced approach to screening where you assess baseline at 40 for all races, so that you can then determine who needs to be screened regularly or not," says Adam Murphy, MD, MBA, MSCI.
“Whenever you're talking about the risk of incontinence, you should know your own data and not cite a specialist who has done a [large amount] of cases,” says Ricardo M. de Oliveira Soares, MD.
“When I'm discussing surgery, or any kind of treatment for prostate cancer, with patients, I always talk about the ‘trifecta,’ “ says Ricardo M. de Oliveira Soares, MD.
"In our lab, we found that when you gave it to the mice model of bladder cancer, the tumors go away, and they're infiltrated with immune cells," says Joshua J. Meeks, MD, PhD.
“There are a number of trials that we're interested in to develop potentially combining chemotherapy and neoadjuvant immunotherapy,” says Joshua J. Meeks, MD, PhD.
Ashley E. Ross, MD, PhD, provides an overview of his institution’s new protocol for this subset of patients.
"Augmented biopsy-based and noninvasive options are available to reduce benign resection rates of renal tumors with the consideration of PEER and 99mTc-sestamibi SPECT/CT," writes Hiten D. Patel, MD, MPH.
